Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients

被引:22
作者
Shields, Carol L. [1 ]
Di Nicola, Maura [1 ]
Bekerman, Vladislav P. [1 ]
Kaliki, Swathi [1 ]
Alarcon, Carolina [1 ]
Fulco, Enzo [1 ]
Shields, Jerry A. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Hosp, Ocular Oncol Serv, 840 Walnut St,Suite 1440, Philadelphia, PA 19107 USA
关键词
UVEAL MELANOMA; PROGNOSIS; MANAGEMENT; TUMORS; EYES; AGE;
D O I
10.1016/j.ophtha.2017.11.040
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The American Joint Committee on Cancer (AJCC) classification was updated to the eighth edition in January 2017, providing staging for iris melanoma. This study evaluated outcomes of iris melanoma per the AJCC classification, eighth edition. Design: Retrospective case series. Participants: Four hundred thirty-two patients with iris melanoma. Methods: Management including tumor resection, plaque radiotherapy, or enucleation. Main Outcome Measures: Local tumor recurrence, melanoma-related systemic metastasis, and melanoma-related death. Results: Of 432 patients with iris melanoma, AJCC classification was category T1 (n = 324 [75%]), T2 (n = 83 [19%]), T3 (n = 2 [< 1%]), and T4 (n = 23 [5%]). There was no difference in age, race, gender, eye, or iris color among T categories. Overall, Kaplan-Meier analysis of outcomes (at 5 and 10 years) revealed visual acuity reduction by 3 lines or more (42% and 54%, respectively), secondary glaucoma (29% and 33%, respectively), local recurrence (8% and 17%, respectively), secondary enucleation (12% and 19%, respectively), lymph node metastasis (1% and 1%, respectively), melanoma-related systemic metastasis (5% and 10%, respectively), and melanoma-related death (3% and 4%, respectively). Compared with T1 category, the hazard ratio (HR) for local recurrence in nonenucleated eyes was 1.31 for T2, not evaluable (NE) for T3 (because of small cohort), and 6.61 for T4; the HR for metastasis was 3.41 for T2, NE for T3 (because of small cohort), and 25.6 for T4; the HR for death was 7.51 for T2, NE for T3 (because of small cohort), and 26.5 for T4; and the odds ratio for enucleation was 1.23 for T2, 3.63 for T3, and 4.72 for T4. Features predictive of melanoma-related metastasis (multivariate analysis) included secondary glaucoma (P < 0.001; HR, 4.51), T2 category (vs. T1; P = 0.01; HR, 4.09), and T4 category (vs. T1; P < 0.001; HR, 30.8). Features predictive of melanoma-related death (multivariate analysis) included older age (P = 0.008; HR, 2.16 per 10-year increase), T2 category (vs. T1; P = 0.005; HR, 8.07), and T4 category (vs. T1; P < 0.001; HR, 20.3). Conclusions: The AJCC eighth edition classification provides prognostic stratification of iris melanoma. By multivariate analysis, the ratio for melanoma-related metastasis was 4 times greater in category T2 and 31 times greater in T4 compared with T1. The ratio for melanoma-related death was 8 times greater in category T2 and 20 times greater in T4 compared with T1. The cohort size for T3 was too small to provide useful information. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:913 / 923
页数:11
相关论文
共 16 条
[1]  
Bekerman VP., 2017, RETINA TODAY, P40
[2]   International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma [J].
Finger, Paul T. .
JAMA OPHTHALMOLOGY, 2015, 133 (04) :376-383
[3]   Clinical and Pathologic Characteristics of Biopsy-Proven Iris Melanoma A Multicenter International Study [J].
Khan, Samira ;
Finger, Paul T. ;
Yu, Guo-Pei ;
Razzaq, Lubna ;
Jager, Martine J. ;
de Keizer, Rob J. W. ;
Sandkull, Per ;
Seregard, Stefan ;
Gologorsky, Daniel ;
Schefler, Amy C. ;
Murray, Timothy G. ;
Kivela, Tero ;
Giuliari, Gian Paolo ;
McGowan, Hugh ;
Simpson, E. Rand ;
Corriveau, Christine ;
Coupland, Sarah E. ;
Damato, Bertil E. .
ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (01) :57-64
[4]  
Kivela T., 2017, AJCC Cancer Staging Manual, V8:th, P805
[5]   The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death [J].
Kivela, Tero .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (09) :1129-1131
[6]   Radiotherapeutic and surgical management of iris melanoma: A review [J].
Popovic, Marko ;
Ahmed, Iqbal Ike K. ;
DiGiovanni, Julia ;
Shields, Carol L. .
SURVEY OF OPHTHALMOLOGY, 2017, 62 (03) :302-311
[7]   Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture [J].
Shields, C. L. ;
Kaliki, S. ;
Cohen, M. N. ;
Shields, P. W. ;
Furuta, M. ;
Shields, J. A. .
EYE, 2015, 29 (08) :1027-1035
[8]  
Shields Carol L, 2013, Oman J Ophthalmol, V6, P159, DOI 10.4103/0974-620X.122269
[9]   Iris Nevus Growth into Melanoma: Analysis of 1611 Consecutive Eyes The ABCDEF Guide [J].
Shields, Carol L. ;
Kaliki, Swathi ;
Hutchinson, Anne ;
Nickerson, Stephanie ;
Patel, Jinali ;
Kancherla, Swarupa ;
Peshtani, Ani ;
Nakhoda, Shazia ;
Kocher, Kristen ;
Kolbus, Emily ;
Jacobs, Emily ;
Garoon, Robert ;
Walker, Brianna ;
Rogers, Brittany ;
Shields, Jerry A. .
OPHTHALMOLOGY, 2013, 120 (04) :766-772
[10]   Iris Melanoma Management with Iodine-125 Plaque Radiotherapy in 144 Patients: Impact of Melanoma-Related Glaucoma on Outcomes [J].
Shields, Carol L. ;
Shah, Sanket U. ;
Bianciotto, Carlos G. ;
Emrich, Jacqueline ;
Komarnicky, Lydia ;
Shields, Jerry A. .
OPHTHALMOLOGY, 2013, 120 (01) :55-61